InnoCare Pharma’s Zurletrectinib (ICP-723) Granted Priority Review by China’s CDE

China’s Center for Drug Evaluation (CDE), a division of the National Medical Products Administration (NMPA), has accepted zurletrectinib (ICP-723), a drug developed by InnoCare Pharma, for priority review. The acceptance of priority review indicates the CDE will expedite the evaluation process for zurletrectinib. InnoCare Pharma developed zurletrectinib, but further details about the drug itself or the reasons for the priority review designation were not disclosed.

Newsflash | Powered by GeneOnline AI
Date: May 5, 2025

Related posts:

Alivus Life Sciences’ Ms. Veera to Attend Mumbai PLI Conclave 2025 on February 21 Pharmaceutical Industry Update: Value-Based Pricing Emerges as R&D Advances Gene Therapy. US Flu Season Sees Highest Pediatric Death Toll Since 2009 Swine Flu Pandemic Medical Conference Focuses on Individual Factors in Statin Therapy, Including Liver/Kidney Disease Considerations

Author

Mark Chiang